UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$589.14 USD
-5.18 (-0.87%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $589.50 +0.36 (0.06%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$589.14 USD
-5.18 (-0.87%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $589.50 +0.36 (0.06%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Is Trending Stock UnitedHealth Group Incorporated (UNH) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.
Earnings Growth & Price Strength Make UnitedHealth Group (UNH) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Beat the Market Like Zacks: Motorola, UnitedHealth, Virtu in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Should SPDR Dow Jones Industrial Average ETF (DIA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DIA
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Cigna (CI) Q2 Earnings Top on Specialty Business Strength
by Zacks Equity Research
Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Ensign Group (ENSG) Q2 Earnings Beat on Occupancy, Stock Up 7.2%
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancy and skilled services revenue. Higher expenses partially offset the results.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?
by Kaibalya Pravo Dey
UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.
Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership
by Zacks Equity Research
Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna and Centene
by Zacks Equity Research
UnitedHealth, The Cigna and Centene are part of the Zacks Industry Outlook article.
Here's Why UnitedHealth Group (UNH) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Community Health (CYH) Q2 Earnings Miss on Lower Patient Days
by Zacks Equity Research
Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
3 HMO Stocks Set to Thrive on a Varied Customer Base, Tech Investments
by Debasmita Chatterjee
Rising premiums, technological advancements and increased demand for Medicare plans are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI and CNC are poised to benefit from encouraging industry prospects.
Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.
Why UnitedHealth Group (UNH) is a Top Stock for the Long-Term
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.